Figure 1.
Figure 1. Plasma CXCL9, CXCL10, and CXCL11 levels are elevated in patients with current HCV infection. (A) CXCL10 was measured by cytometric bead array, and levels were confirmed by ELISA in control subjects (n = 58), sustained responders (SVR; n = 51), and patients with HCV (n = 82). (B) CXCL9 was measured by cytometric bead array, and levels were confirmed by ELISA in control subjects (n = 44), sustained responders (n = 50), and patients with HCV (n = 82). (C) CXCL11 was measured by ELISA in control subjects (n = 44), sustained responders (n = 47), and patients with HCV (n = 81). Lines across each column represent the median value for each set of measurements. Values of P at the top of each graph were calculated by the Kruskal-Wallis test. Dunn multiple comparison test was used as a posttest to compare each group of samples to each other group; NS indicates not significant; **P < .01; ***P < .001.

Plasma CXCL9, CXCL10, and CXCL11 levels are elevated in patients with current HCV infection. (A) CXCL10 was measured by cytometric bead array, and levels were confirmed by ELISA in control subjects (n = 58), sustained responders (SVR; n = 51), and patients with HCV (n = 82). (B) CXCL9 was measured by cytometric bead array, and levels were confirmed by ELISA in control subjects (n = 44), sustained responders (n = 50), and patients with HCV (n = 82). (C) CXCL11 was measured by ELISA in control subjects (n = 44), sustained responders (n = 47), and patients with HCV (n = 81). Lines across each column represent the median value for each set of measurements. Values of P at the top of each graph were calculated by the Kruskal-Wallis test. Dunn multiple comparison test was used as a posttest to compare each group of samples to each other group; NS indicates not significant; **P < .01; ***P < .001.

Close Modal

or Create an Account

Close Modal
Close Modal